2008 JASN IMPACT FACTOR 7.505	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text (Rapid PDF) All Versions of this Article: ASN.2007121377v1 19/5/863    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vanholder, R. Search for Related Content PubMed PubMed Citation Articles by Vanholder, R.

UP FRONT MATTERS

A Bench to Bedside View of Uremic Toxins

Raymond Vanholder ^*1, Ulrich Baurmeister , Philippe Brunet , Gerald Cohen , Griet Glorieux ^*, Joachim Jankowski ^||, and for the European Uremic Toxin Work Group

*Nephrology Section, Department of Internal Medicine, University Hospital, Ghent, Belgium; Nephrology and Medical Intensive Care, University Hospital Charité, Campus Virchow-Klinikum, Berlin, Germany; Néphrologie, Hôpital Conception and INSERM U608, Université Aix-Marseille, France; Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria; and ||Charité, Medizinische Klinik IV, Berlin, Germany

¹ To whom correspondence should be addressed. E-mail: raymond.vanholder{at}ugent.be.

	Abstract

Reviewing the current picture of uremic toxicity reveals its complexity. Focusing on cardiovascular damage as a model of uremic effects resulting in substantial morbidity and mortality, most molecules with potential to affect the function of a variety of cell types within the vascular system are difficult to remove by dialysis. Examples are the larger middle molecular weight molecules and protein-bound molecules. Recent clinical studies suggest that enhancing the removal of these compounds is beneficial for survival. Future therapeutic options are discussed, including improved removal of toxins and the search for pharmacologic strategies blocking responsible pathophysiologic pathways.

This article has been cited by other articles:

				F. C. Barreto, D. V. Barreto, S. Liabeuf, N. Meert, G. Glorieux, M. Temmar, G. Choukroun, R. Vanholder, Z. A. Massy, and on behalf of the European Uremic Toxin Work Group Serum Indoxyl Sulfate Is Associated with Vascular Disease and Mortality in Chronic Kidney Disease Patients Clin. J. Am. Soc. Nephrol., October 1, 2009; 4(10): 1551 - 1558. [Abstract] [Full Text] [PDF]

				S. Eloot, W. van Biesen, A. Dhondt, R. de Smet, B. Marescau, P. P. De Deyn, P. Verdonck, and R. Vanholder Impact of increasing haemodialysis frequency versus haemodialysis duration on removal of urea and guanidino compounds: a kinetic analysis Nephrol. Dial. Transplant., July 1, 2009; 24(7): 2225 - 2232. [Abstract] [Full Text] [PDF]

				T. Ookoshi, K. Hasegawa, Y. Ohhashi, H. Kimura, N. Takahashi, H. Yoshida, R. Miyazaki, Y. Goto, and H. Naiki Lysophospholipids induce the nucleation and extension of {beta}2-microglobulin-related amyloid fibrils at a neutral pH Nephrol. Dial. Transplant., October 1, 2008; 23(10): 3247 - 3255. [Abstract] [Full Text] [PDF]

Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673